A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis
MuSK-MG showed distinct clinical and immunological features, including predominant bulbar/limb onset, elevated CD19<sup>+</sup>B and memory B cells, and disease severity associated CD4<sup>+</sup>T, CD19<sup>+</sup>B and NK-cell alterations. In patients with MuSK-MG, low-dose RTX may be associated with long-term and sustained clinical improvement.
Authors
- Yong Zhang (ORCID: https://orcid.org/0000-0001-5908-5094)
- Xinyan Guo
- Mingjin Yang (ORCID: https://orcid.org/0009-0006-2208-4876)
- Xue Du (ORCID: https://orcid.org/0000-0001-9424-0520)
- Fengzhan Li (ORCID: https://orcid.org/0000-0003-3834-4872)
- Tianyu Ma (ORCID: https://orcid.org/0000-0002-2326-5760)
- Zhouao Zhang (ORCID: https://orcid.org/0009-0000-6253-6167)
- Luyao Su
- Tiancheng Luo (ORCID: https://orcid.org/0000-0002-8309-4158)
- Xiaoyu Huang
- Yuting Li
- Deliang Peng
- Zhouyi Wang (ORCID: https://orcid.org/0009-0002-8690-247X)
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1624038
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Xuzhou Medical University